Reyhaneh Moradi-Marjaneh, Majid Khazaei, Sima Seifi, Seyed Mahdi Hassanian, Gordon A. Ferns and Amir Avan* Pages 2710 - 2718 ( 9 )
Inter-individual differences in drug response are an important cause of failure in anticancer treatment and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been investigated in an effort to find new genetic biomarkers to predict toxicity and response to anticancer drugs. Evaluating the value single nucleotide polymorphisms (SNPs) in the genes involved in transportation, activation and metabolism of anticancer drugs provides a promising approach to select the appropriate therapeutic regimes with at least adverse reactions. This review summarizes the current knowledge about the relationship between of SNPs involved in the transportation, activation and metabolism of anticancer drugs and treatment outcomes in colorectal cancer (CRC) patients.
Colorectal cancer, polymorphisms, anticancer drugs, pharmacogenetics, gene polymorphisms, single nucleotide polymorphisms.
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad